News
News from us and our partners
News
News
Capital
News
Biovelocita
News
Crossover
News
Capital
News
News
Capital
In memory of Denis Lucquin, Sofinnova chairman
Sofinnova Partners closes Capital XI at €650M
Sofinnova Partners exceeds target with €165M biotech acceleration fund, Europe’s largest, with strong Pharma support
CEO spotlight: Thierry Abribat's third straight win
Johnson & Johnson to acquire Shockwave Medical
CEO spotlight: CinCor's Marc de Garidel
Sofinnova Partners announces Myricx Bio agrees to be acquired by Novartis
Tags
Topics
0 results
- News
Seven years: the journey behind Myricx's acquisition by Novartis
- News
Sofinnova Partners announces Myricx Bio agrees to be acquired by Novartis
- News
Muna Therapeutics Announces CEO Transition as Clinical Pipeline Advances
- News
Partnership with French cancer research network FFCD expands Bioptimus’s STELA programme
- News
Moon Surgical and Uncovr Announce First 20 Clinical Cases of Automated Operative Reporting on Maestro®
- News
“Health is Wealth”: Why Europe must act now to strengthen its Life Sciences industry
- News
Mediar Therapeutics Announces First Cohorts Dosed in Phase 1 Clinical Trial of MTX-439 for Fibrosis Associated with Chronic Kidney Disease (CKD) and Additions to Clinical Advisory Board
- News
TISSIUM secures €60 million to support commercial and clinical activities and platform expansion
- News
BrightHeart Announces CE Mark and European Launch of its AI Platform for Prenatal Ultrasound
- News
Micropep Files First Regulatory Submissions for Promisin™, a Novel Peptide Biofungicide with a New Mode of Action
- News
How a Sofinnova Partner's thesis became a $165M biotech
- News
Bionyra Pharma Launches with $165 million Oversubscribed Series A to Advance Clinical Stage Pipeline of Next Generation Biologics for Immune-Mediated Inflammatory Diseases
- News
Sitryx Completes Enrollment in Phase 1b Trial of First-in-Class Oral PKM2 Modulator SYX-5219 in Atopic Dermatitis
- News
F2G and Shionogi Announce Positive Topline Results from Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients with Invasive Aspergillosis
- News
Germany’s top research institutions and venture capital investors unite behind spin-off framework